ZA200700143B - Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients - Google Patents

Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients

Info

Publication number
ZA200700143B
ZA200700143B ZA200700143A ZA200700143A ZA200700143B ZA 200700143 B ZA200700143 B ZA 200700143B ZA 200700143 A ZA200700143 A ZA 200700143A ZA 200700143 A ZA200700143 A ZA 200700143A ZA 200700143 B ZA200700143 B ZA 200700143B
Authority
ZA
South Africa
Prior art keywords
memantine
atypical antipsychotics
adjunctive treatment
schizophrenia patients
schizophrenia
Prior art date
Application number
ZA200700143A
Other languages
English (en)
Inventor
Jonas Jeffery
Gage Allyson
Original Assignee
Forest Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35116165&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200700143(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Forest Laboratories filed Critical Forest Laboratories
Publication of ZA200700143B publication Critical patent/ZA200700143B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200700143A 2004-07-09 2007-01-04 Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients ZA200700143B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58655304P 2004-07-09 2004-07-09

Publications (1)

Publication Number Publication Date
ZA200700143B true ZA200700143B (en) 2008-11-26

Family

ID=35116165

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200700143A ZA200700143B (en) 2004-07-09 2007-01-04 Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients

Country Status (14)

Country Link
US (1) US20060035888A1 (xx)
EP (1) EP1781273A2 (xx)
JP (1) JP2008505923A (xx)
CN (1) CN1984645A (xx)
AR (1) AR049844A1 (xx)
AU (1) AU2005271906A1 (xx)
BR (1) BRPI0513168A (xx)
CA (1) CA2573091A1 (xx)
EA (1) EA200700214A1 (xx)
IL (1) IL180575A0 (xx)
MX (1) MX2007000713A (xx)
TW (1) TW200616608A (xx)
WO (1) WO2006017188A2 (xx)
ZA (1) ZA200700143B (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101157272B1 (ko) 2003-07-22 2012-06-15 아레나 파마슈티칼스, 인크. 5?ｈｔ2ａ 세로토닌 수용체의 조절자로서 이와 관련된질환의 예방 및 치료에 유용한 디아릴 및 아릴헤테로아릴우레아 유도체
WO2007132476A2 (en) * 2006-05-15 2007-11-22 Matrix Laboratories Limited A process for the preparation of memantine hydrochloride
EP1886670A1 (en) * 2006-07-05 2008-02-13 Teva Pharmaceutical Industries Ltd Pharmaceutical compositions of memantine
RU2326660C1 (ru) * 2007-03-14 2008-06-20 Закрытое акционерное общество "Биологические исследования и системы" Пероральный лекарственный препарат мемантин (варианты) и способ его получения (варианты)
GB0713930D0 (en) * 2007-07-18 2007-08-29 Generics Uk Ltd Novel assay methods
EP2508177A1 (en) 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US20090275597A1 (en) * 2008-05-02 2009-11-05 Forest Laboratories Holdings Limited Methods of treating cns disorders
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
WO2010126527A1 (en) * 2009-05-01 2010-11-04 Forest Laboratories Holdings Limited Methods of treating cns disorders
US9242009B2 (en) 2012-07-17 2016-01-26 The General Hospital Corporation Compositions and methods to treat neurodegenerative diseases
WO2014144115A1 (en) * 2013-03-15 2014-09-18 Shire Llc Fixed dose combination treatment for schizophrenia
EP4119141A1 (en) 2015-06-12 2023-01-18 Axovant Sciences GmbH Nelotanserin for the prophylaxis and treatment of rem sleep behavior disorder
JP2018520187A (ja) 2015-07-15 2018-07-26 アクソヴァント サイエンシーズ ゲゼルシャフト ミット ベシュレンクテル ハフツングAxovant Sciences GmbH 神経変性疾患と関連する幻覚の予防および処置のために有用な５−ｈｔ２ａセロトニン受容体のモジュレーターとしてのジアリールおよびアリールヘテロアリール尿素誘導体
US11541018B2 (en) 2016-06-23 2023-01-03 Corium, Llc Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent
JP7251033B2 (ja) 2016-07-27 2023-04-04 コリウム， エルエルシー ドネペジル経皮送達システム
CN109789113A (zh) 2016-07-27 2019-05-21 考里安国际公司 美金刚透皮递送系统
EP3490559A1 (en) 2016-07-27 2019-06-05 Corium International, Inc. Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery
AU2018392686A1 (en) * 2017-12-20 2020-07-09 Corium Pharma Solutions, Inc. Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
ES413944A1 (es) * 1972-04-20 1976-06-01 Merz & Co Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5.
JPS54130587A (en) * 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
DE2856393C2 (de) * 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
US5366738A (en) * 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE58370B1 (en) * 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US6024983A (en) * 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US4849222A (en) * 1987-03-24 1989-07-18 The Procter & Gamble Company Mixtures for treating hypercholesterolemia
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
US5506231A (en) * 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US5334618A (en) * 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5238945A (en) * 1989-04-11 1993-08-24 H. Lundbeck A/S Method of treating psychoses
GB8908085D0 (en) * 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
ATE94384T1 (de) * 1989-04-14 1993-10-15 Merz & Co Gmbh & Co Verwendung von adamantan-derivaten zur praevention und behandlung der cerebralen ischaemie.
US5614560A (en) * 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US20040102525A1 (en) * 2002-05-22 2004-05-27 Kozachuk Walter E. Compositions and methods of treating neurological disease and providing neuroprotection
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
MXPA06014587A (es) * 2004-06-17 2007-04-27 Forest Laboratories Formulaciones de liberacion modificada de formulaciones de dosificacion oral de memantina.

Also Published As

Publication number Publication date
AR049844A1 (es) 2006-09-06
WO2006017188A2 (en) 2006-02-16
IL180575A0 (en) 2008-04-13
CN1984645A (zh) 2007-06-20
BRPI0513168A (pt) 2008-04-29
CA2573091A1 (en) 2006-02-16
TW200616608A (en) 2006-06-01
JP2008505923A (ja) 2008-02-28
AU2005271906A1 (en) 2006-02-16
EP1781273A2 (en) 2007-05-09
WO2006017188A3 (en) 2006-06-29
MX2007000713A (es) 2007-03-30
US20060035888A1 (en) 2006-02-16
EA200700214A1 (ru) 2007-06-29

Similar Documents

Publication Publication Date Title
ZA200700143B (en) Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
GB2455625B (en) The use of benzoquinones and hydroquinones as antibacterial agents in the treatment of periodontal diseases
EP1942981A4 (en) DISTRIBUTION OF MEDIUM TO TISSUE
IL191317A (en) Use of cells for the preparation of a pharmaceutical preparation for complementary treatment
EP1758450A4 (en) IMPROVEMENTS AT BZW. REGARDLESS PLANT TREATMENT AGENTS
GB0517103D0 (en) Improvements in or relating to specula
EP1730148A4 (en) USE OF AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS
EP1731113A4 (en) MEDICAL TREATMENT KIT
GB0427444D0 (en) Improvements relating to skin dressings
GB2429400B (en) Improvements in or relating to baby care
PL2125004T3 (pl) Synergiczne zastosowanie terapeutyczne koncentratów czynników zespołu protrombiny z koncentratami FVIII
GB0700235D0 (en) Improvements relating to medical devices
GB0321911D0 (en) Improvements in or relating to medical devices
IL201438A0 (en) Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease
GB0523026D0 (en) Patient table
GB2459076B (en) Improvements in and relating to medical devices
GB2444577B (en) Improvements to grass treatment devices
GB0410586D0 (en) Improvements relating to patient turning devices
GB0415181D0 (en) Compounds for use in the treatment of infection
GB0710277D0 (en) Use of antivirals in the treatment of medical disorders
GB0523291D0 (en) Treatment table
GB0413889D0 (en) Improvements relating to fabric treatment
GB0415197D0 (en) Improvements in or relating to medical devices
GB0413668D0 (en) Improvements to cannula components
GB0510464D0 (en) Improvements in or relating to medical treatments